A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells [clinicaltrials:NCT00000822]
A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells [clinicaltrials:NCT00000822]
Bio2RDF identifier
NCT00000822
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00000822
identifiers.org URI
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
To evaluate the safety ...... th disease
progression.
brief title [clinicaltrials_vocabulary:brief-title]
A Phase I/II Double-Blind Cont ...... s and 200-400/mm3 CD4+ T Cells
collaborator [clinicaltrials_vocabulary:collaborator]
completion date [clinicaltrials_vocabulary:completion-date]
1999-05-01T00:00:00Z
condition [clinicaltrials_vocabulary:condition]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
HIV-specific cellular i ...... de for injection
(USP).
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
enrollment [clinicaltrials_vocabulary:enrollment]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
1999-11-02T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]
is section 801 [clinicaltrials_vocabulary:is-section-801]
keyword [clinicaltrials_vocabulary:keyword]
AIDS Vaccines
AIDS-Related Complex
Acquired Immunodeficiency Syndrome
Didanosine
Drug Therapy, Combination
HIV Envelope Protein gp160
HIV Protease Inhibitors
HIV Therapeutic Vaccine
Reverse Transcriptase Inhibitors
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2012-05-08T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
link [clinicaltrials_vocabulary:link]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00000822
official title [clinicaltrials_vocabulary:official-title]
A Phase I/II Double-Blind Cont ...... s and 200-400/mm3 CD4+ T Cells
org study id [clinicaltrials_vocabulary:org-study-id]
ACTG 246/946
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
reference [clinicaltrials_vocabulary:reference]
responsible party [clinicaltrials_vocabulary:responsible-party]
secondary id [clinicaltrials_vocabulary:secondary-id]
source [clinicaltrials_vocabulary:source]
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2012-05-01T00:00:00Z
identifier
clinicaltrials:NCT00000822
title
A Phase I/II Double-Blind Cont ...... s and 200-400/mm3 CD4+ T Cells
@en
type
label
A Phase I/II Double-Blind Cont ...... s [clinicaltrials:NCT00000822]
@en